28.06.2021 14:28:36

Eiger Announces Positive Phase 2 Results Of Avexitide In Congenital Hyperinsulinism

(RTTNews) - Eiger BioPharmaceuticals, Inc. (EIGR) announced a presentation of positive phase 2 study results of Avexitide in congenital hyperinsulinism. Avexitide infusion demonstrated significant reductions in glucose infusion requirements to maintain euglycemia or normal glucose levels in neonates and infants. Avexitide represents a promising, targeted approach for the treatment of congenital hyperinsulinism.

Avexitide is a targeted, first-in-class, GLP-1 antagonist in development for the treatment of hyperinsulinism, an ultra-rare, life-threatening, pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children.

Avexitide 100, 200 and 1,000 pmol/kg/min ascending doses demonstrated 1.3 (15%), 2.9 (24%), and 4.3 (56%) mg/kg/min reductions in glucose infusion rate relative to placebo, respectively, and entirely abolished the glucose requirement in 50% of patients at the top dose.

Avexitide was well-tolerated in this study. Adverse events were typically mild in severity and transient, and there were no serious adverse events.

Nachrichten zu Eiger BioPharmaceuticals Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Eiger BioPharmaceuticals Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!